{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:16Z","timestamp":1793422636404,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The autoimmune response in type 1 diabetes (T1D), in which the beta cells expressing aberrant or modified proteins are killed, resembles an effective antitumor response. Defective ribosomal protein products in tumors are targets of the anti-tumor immune response that is unleashed by immune checkpoint inhibitor (ICI) treatment in cancer patients. We recently described a defective ribosomal product of the insulin gene (INS-DRiP) that is expressed in stressed beta cells and targeted by diabetogenic T cells. T1D patient-derived INS-DRiP specific T cells can kill beta cells and are present in the insulitic lesion. T cells reactive to INS-DRiP epitopes are part of the normal T cell repertoire and are believed to be kept in check by immune regulation without causing autoimmunity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>T cell autoreactivity was tested using a combinatorial HLA multimer technology measuring a range of epitopes of islet autoantigens and neoantigen INS-DRiP. INS-DRiP expression in human pancreas and insulinoma sections was tested by immunohistochemistry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Here we report the induction of islet autoimmunity to INS-DRiP and diabetes after ICI treatment and successful tumor remission. Following ICI treatment, T cells of the cancer patient were primed against INS-DRiP among other diabetogenic antigens, while there was no sign of autoimmunity to this neoantigen before ICI treatment. Next, we demonstrated the expression of INS-DRiP as neoantigen in both pancreatic islets and insulinoma by staining with a monoclonal antibody to INS-DRiP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These results bridge cancer and T1D as two sides of the same coin and point to neoantigen expression in normal islets and insulinoma that may serve as target of both islet autoimmunity and tumor-related autoimmunity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1384406","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:23:38Z","timestamp":1711427018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Induction of islet autoimmunity to defective ribosomal product of the insulin gene as neoantigen after anti-cancer immunotherapy leading to autoimmune diabetes"],"prefix":"10.3389","volume":"15","author":[{"given":"Rene","family":"van Tienhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diahann T. S. L.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Quezada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart O.","family":"Roep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1084\/jem.20111187","article-title":"Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients","volume":"209","author":"Coppieters","year":"2012","journal-title":"J Exp Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0779","article-title":"Insulitis and beta-cell mass in the natural history of type 1 diabetes","volume":"65","author":"Campbell-Thompson","year":"2016","journal-title":"Diabetes"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4289","article-title":"Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes","volume":"23","author":"Kracht","year":"2017","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.coi.2016.09.007","article-title":"A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes","volume":"43","author":"Roep","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.03.013","article-title":"Neoantigens and microenvironment in type 1 diabetes: lessons from antitumor immunity","volume":"27","author":"Kracht","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.5.1823","article-title":"Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules","volume":"157","author":"Yewdell","year":"1996","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107208118","article-title":"Human islet T cells are highly reactive to preproinsulin in type 1 diabetes","volume":"118","author":"Anderson","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19585","article-title":"Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health","volume":"113","author":"Arif","year":"2004","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.5967","article-title":"Autoreactive T cells in healthy individuals","volume":"172","author":"Danke","year":"2004","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aao4013","article-title":"Islet-reactive CD8(+) T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors","volume":"3","author":"Culina","year":"2018","journal-title":"Sci Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.3.278","article-title":"T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM","volume":"44","author":"Roep","year":"1995","journal-title":"Diabetes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.09.040","article-title":"PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via IRF1 induction","volume":"36","author":"Colli","year":"2018","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1515\/med-2020-0110","article-title":"Efficacy of pembrolizumab for advanced\/metastatic melanoma: a meta-analysis","volume":"15","author":"Zhang","year":"2020","journal-title":"Open Med (Wars)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0740","article-title":"Anti-PD-1 therapy-associated type 1 diabetes in a pediatric patient with relapsed classical hodgkin lymphoma","volume":"43","author":"Samoa","year":"2020","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1486","article-title":"Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers","volume":"59","author":"Velthuis","year":"2010","journal-title":"Diabetes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"191ra182","DOI":"10.1126\/scitranslmed.3006103","article-title":"Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes","volume":"5","author":"Roep","year":"2013","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00826-3","article-title":"Why does the immune system destroy pancreatic beta-cells but not alpha-cells in type 1 diabetes","volume":"19","author":"Eizirik","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689076","article-title":"Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer","volume":"12","author":"Zou","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1214","article-title":"Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes","volume":"63","author":"van Lummel","year":"2014","journal-title":"Diabetes"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05882-y","article-title":"Presence of immunogenic alternatively spliced insulin gene product in human pancreatic delta cells","volume":"66","author":"van Tienhoven","year":"2023","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05991-8","article-title":"IFN\u03b3 but not IFNalpha increases recognition of insulin defective ribosomal product-derived antigen to amplify islet autoimmunity","volume":"66","author":"Thomaidou","year":"2023","journal-title":"Diabetologia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384406\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:23:40Z","timestamp":1711427020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1384406\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2024.1384406"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1384406","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"article-number":"1384406"}}